Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 91


How to Qualify Container Closure Systems for Intended Use, Part 1.

Kim AA, Gehrmann MR, McCaw J, McAndrew TP.

Int J Pharm Compd. 2019 Nov-Dec;23(6):454-461. Erratum in: Int J Pharm Compd. 2020 Jan-Feb;24(1):86-87.


Long-Term Study of Container Closure Integrity of Rubber-Glass Vial Systems by Multiple Methods.

Gehrmann MR, Mcandrew TP.

PDA J Pharm Sci Technol. 2020 Jan-Feb;74(1):147-161. doi: 10.5731/pdajpst.2019.010223. Epub 2019 Aug 16.


Implementing Reverse Phase Protein Array Profiling as a Sensitive Method for the Early Pre-Clinical Detection of Off-Target Toxicities Associated with Sunitinib Malate.

O'Farrell AC, Miller IS, Evans R, Alamanou M, Cary M, Mallya Udupi G, Lafferty A, Monsefi N, Cremona M, Prehn JHM, Verheul HM, Gallagher WM, Gehrmann M, Byrne AT.

Proteomics Clin Appl. 2019 Jul;13(4):e1800159. doi: 10.1002/prca.201800159. Epub 2019 Mar 19.


Molecular AFM imaging of Hsp70-1A association with dipalmitoyl phosphatidylserine reveals membrane blebbing in the presence of cholesterol.

Lamprecht C, Gehrmann M, Madl J, Römer W, Multhoff G, Ebner A.

Cell Stress Chaperones. 2018 Jul;23(4):673-683. doi: 10.1007/s12192-018-0879-0. Epub 2018 Feb 5.


Overexpression of cytosolic, plasma membrane bound and extracellular heat shock protein 70 (Hsp70) in primary glioblastomas.

Thorsteinsdottir J, Stangl S, Fu P, Guo K, Albrecht V, Eigenbrod S, Erl J, Gehrmann M, Tonn JC, Multhoff G, Schichor C.

J Neurooncol. 2017 Dec;135(3):443-452. doi: 10.1007/s11060-017-2600-z. Epub 2017 Aug 28.


Effects of definitive and salvage radiotherapy on the distribution of lymphocyte subpopulations in prostate cancer patients.

Sage EK, Schmid TE, Geinitz H, Gehrmann M, Sedelmayr M, Duma MN, Combs SE, Multhoff G.

Strahlenther Onkol. 2017 Aug;193(8):648-655. doi: 10.1007/s00066-017-1144-7. Epub 2017 May 12.


Evidence for the Formation of Benzacridine Derivatives in Alkaline-Treated Sunflower Meal and Model Solutions.

Bongartz V, Brandt L, Gehrmann ML, Zimmermann BF, Schulze-Kaysers N, Schieber A.

Molecules. 2016 Jan 14;21(1):91. doi: 10.3390/molecules21010091.


Comparative analysis of the effects of radiotherapy versus radiotherapy after adjuvant chemotherapy on the composition of lymphocyte subpopulations in breast cancer patients.

Sage EK, Schmid TE, Sedelmayr M, Gehrmann M, Geinitz H, Duma MN, Combs SE, Multhoff G.

Radiother Oncol. 2016 Jan;118(1):176-80. doi: 10.1016/j.radonc.2015.11.016. Epub 2015 Dec 9.


Imaging of Hsp70-positive tumors with cmHsp70.1 antibody-conjugated gold nanoparticles.

Gehrmann MK, Kimm MA, Stangl S, Schmid TE, Noël PB, Rummeny EJ, Multhoff G.

Int J Nanomedicine. 2015 Sep 8;10:5687-700. doi: 10.2147/IJN.S87174. eCollection 2015.


Role of membrane Hsp70 in radiation sensitivity of tumor cells.

Murakami N, Kühnel A, Schmid TE, Ilicic K, Stangl S, Braun IS, Gehrmann M, Molls M, Itami J, Multhoff G.

Radiat Oncol. 2015 Jul 22;10:149. doi: 10.1186/s13014-015-0461-1.


Microtubule-associated protein tau correlates with estrogen receptor status but not with in vitro paclitaxel sensitivity in primary breast cancer.

Honig A, Gehrmann M, Kranke P, Keller D, Engel JB, Hengstler S, Schmidt M.

Eur J Gynaecol Oncol. 2014;35(5):503-7.


Tumor imaging and targeting potential of an Hsp70-derived 14-mer peptide.

Gehrmann M, Stangl S, Foulds GA, Oellinger R, Breuninger S, Rad R, Pockley AG, Multhoff G.

PLoS One. 2014 Aug 28;9(8):e105344. doi: 10.1371/journal.pone.0105344. eCollection 2014.


Heat shock protein 70 serum levels differ significantly in patients with chronic hepatitis, liver cirrhosis, and hepatocellular carcinoma.

Gehrmann M, Cervello M, Montalto G, Cappello F, Gulino A, Knape C, Specht HM, Multhoff G.

Front Immunol. 2014 Jul 1;5:307. doi: 10.3389/fimmu.2014.00307. eCollection 2014.


Hsp70--a biomarker for tumor detection and monitoring of outcome of radiation therapy in patients with squamous cell carcinoma of the head and neck.

Gehrmann M, Specht HM, Bayer C, Brandstetter M, Chizzali B, Duma M, Breuninger S, Hube K, Lehnerer S, van Phi V, Sage E, Schmid TE, Sedelmayr M, Schilling D, Sievert W, Stangl S, Multhoff G.

Radiat Oncol. 2014 Jun 9;9:131. doi: 10.1186/1748-717X-9-131.


Validation of heat shock protein 70 as a tumor-specific biomarker for monitoring the outcome of radiation therapy in tumor mouse models.

Bayer C, Liebhardt ME, Schmid TE, Trajkovic-Arsic M, Hube K, Specht HM, Schilling D, Gehrmann M, Stangl S, Siveke JT, Wilkens JJ, Multhoff G.

Int J Radiat Oncol Biol Phys. 2014 Mar 1;88(3):694-700. doi: 10.1016/j.ijrobp.2013.11.008.


The EndoPredict score provides prognostic information on late distant metastases in ER+/HER2- breast cancer patients.

Dubsky P, Brase JC, Jakesz R, Rudas M, Singer CF, Greil R, Dietze O, Luisser I, Klug E, Sedivy R, Bachner M, Mayr D, Schmidt M, Gehrmann MC, Petry C, Weber KE, Fisch K, Kronenwett R, Gnant M, Filipits M; Austrian Breast and Colorectal Cancer Study Group (ABCSG).

Br J Cancer. 2013 Dec 10;109(12):2959-64. doi: 10.1038/bjc.2013.671. Epub 2013 Oct 24.


Targeting by cmHsp70.1-antibody coated and survivin miRNA plasmid loaded nanoparticles to radiosensitize glioblastoma cells.

Gaca S, Reichert S, Multhoff G, Wacker M, Hehlgans S, Botzler C, Gehrmann M, Rödel C, Kreuter J, Rödel F.

J Control Release. 2013 Nov 28;172(1):201-206. doi: 10.1016/j.jconrel.2013.08.020. Epub 2013 Sep 2.


Mitoxantrone targets human ubiquitin-specific peptidase 11 (USP11) and is a potent inhibitor of pancreatic cancer cell survival.

Burkhart RA, Peng Y, Norris ZA, Tholey RM, Talbott VA, Liang Q, Ai Y, Miller K, Lal S, Cozzitorto JA, Witkiewicz AK, Yeo CJ, Gehrmann M, Napper A, Winter JM, Sawicki JA, Zhuang Z, Brody JR.

Mol Cancer Res. 2013 Aug;11(8):901-11. doi: 10.1158/1541-7786.MCR-12-0699. Epub 2013 May 21.


Expression of aurora kinase A is associated with metastasis-free survival in node-negative breast cancer patients.

Siggelkow W, Boehm D, Gebhard S, Battista M, Sicking I, Lebrecht A, Solbach C, Hellwig B, Rahnenführer J, Koelbl H, Gehrmann M, Marchan R, Cadenas C, Hengstler JG, Schmidt M.

BMC Cancer. 2012 Nov 27;12:562. doi: 10.1186/1471-2407-12-562.


Immunoglobulin kappa chain as an immunologic biomarker of prognosis and chemotherapy response in solid tumors.

Schmidt M, Micke P, Gehrmann M, Hengstler JG.

Oncoimmunology. 2012 Oct 1;1(7):1156-1158.


Thymosin beta 15A (TMSB15A) is a predictor of chemotherapy response in triple-negative breast cancer.

Darb-Esfahani S, Kronenwett R, von Minckwitz G, Denkert C, Gehrmann M, Rody A, Budczies J, Brase JC, Mehta MK, Bojar H, Ataseven B, Karn T, Weiss E, Zahm DM, Khandan F, Dietel M, Loibl S.

Br J Cancer. 2012 Nov 20;107(11):1892-900. doi: 10.1038/bjc.2012.475. Epub 2012 Oct 18.


EndoPredict improves the prognostic classification derived from common clinical guidelines in ER-positive, HER2-negative early breast cancer.

Dubsky P, Filipits M, Jakesz R, Rudas M, Singer CF, Greil R, Dietze O, Luisser I, Klug E, Sedivy R, Bachner M, Mayr D, Schmidt M, Gehrmann MC, Petry C, Weber KE, Kronenwett R, Brase JC, Gnant M; Austrian Breast and Colorectal Cancer Study Group (ABCSG).

Ann Oncol. 2013 Mar;24(3):640-7. doi: 10.1093/annonc/mds334. Epub 2012 Oct 3.


Immunoglobulin kappa C predicts overall survival in node-negative breast cancer.

Chen Z, Gerhold-Ay A, Gebhard S, Boehm D, Solbach C, Lebrecht A, Battista M, Sicking I, Cotarelo C, Cadenas C, Marchan R, Stewart JD, Gehrmann M, Koelbl H, Hengstler JG, Schmidt M.

PLoS One. 2012;7(9):e44741. doi: 10.1371/journal.pone.0044741. Epub 2012 Sep 28.


Interferon-inducible guanylate binding protein (GBP2) is associated with better prognosis in breast cancer and indicates an efficient T cell response.

Godoy P, Cadenas C, Hellwig B, Marchan R, Stewart J, Reif R, Lohr M, Gehrmann M, Rahnenführer J, Schmidt M, Hengstler JG.

Breast Cancer. 2014 Jul;21(4):491-9. doi: 10.1007/s12282-012-0404-8. Epub 2012 Sep 22.


Immunotherapeutic targeting of membrane Hsp70-expressing tumors using recombinant human granzyme B.

Gehrmann M, Stangl S, Kirschner A, Foulds GA, Sievert W, Doss BT, Walch A, Pockley AG, Multhoff G.

PLoS One. 2012;7(7):e41341. doi: 10.1371/journal.pone.0041341. Epub 2012 Jul 19.


A comprehensive analysis of human gene expression profiles identifies stromal immunoglobulin κ C as a compatible prognostic marker in human solid tumors.

Schmidt M, Hellwig B, Hammad S, Othman A, Lohr M, Chen Z, Boehm D, Gebhard S, Petry I, Lebrecht A, Cadenas C, Marchan R, Stewart JD, Solbach C, Holmberg L, Edlund K, Kultima HG, Rody A, Berglund A, Lambe M, Isaksson A, Botling J, Karn T, Müller V, Gerhold-Ay A, Cotarelo C, Sebastian M, Kronenwett R, Bojar H, Lehr HA, Sahin U, Koelbl H, Gehrmann M, Micke P, Rahnenführer J, Hengstler JG.

Clin Cancer Res. 2012 May 1;18(9):2695-703. doi: 10.1158/1078-0432.CCR-11-2210. Epub 2012 Feb 20.


A new molecular predictor of distant recurrence in ER-positive, HER2-negative breast cancer adds independent information to conventional clinical risk factors.

Filipits M, Rudas M, Jakesz R, Dubsky P, Fitzal F, Singer CF, Dietze O, Greil R, Jelen A, Sevelda P, Freibauer C, Müller V, Jänicke F, Schmidt M, Kölbl H, Rody A, Kaufmann M, Schroth W, Brauch H, Schwab M, Fritz P, Weber KE, Feder IS, Hennig G, Kronenwett R, Gehrmann M, Gnant M; EP Investigators.

Clin Cancer Res. 2011 Sep 15;17(18):6012-20. doi: 10.1158/1078-0432.CCR-11-0926. Epub 2011 Aug 1.


A novel expression and purification system for the production of enzymatic and biologically active human granzyme B.

Gehrmann M, Doss BT, Wagner M, Zettlitz KA, Kontermann RE, Foulds G, Pockley AG, Multhoff G.

J Immunol Methods. 2011 Aug 31;371(1-2):8-17. doi: 10.1016/j.jim.2011.06.007. Epub 2011 Jun 22.


Gene expression profiling of luminal B breast cancers reveals NHERF1 as a new marker of endocrine resistance.

Karn T, Ruckhäberle E, Hanker L, Müller V, Schmidt M, Solbach C, Gätje R, Gehrmann M, Holtrich U, Kaufmann M, Rody A.

Breast Cancer Res Treat. 2011 Nov;130(2):409-20. doi: 10.1007/s10549-010-1333-x. Epub 2011 Jan 4.


Targeting membrane heat-shock protein 70 (Hsp70) on tumors by cmHsp70.1 antibody.

Stangl S, Gehrmann M, Riegger J, Kuhs K, Riederer I, Sievert W, Hube K, Mocikat R, Dressel R, Kremmer E, Pockley AG, Friedrich L, Vigh L, Skerra A, Multhoff G.

Proc Natl Acad Sci U S A. 2011 Jan 11;108(2):733-8. doi: 10.1073/pnas.1016065108. Epub 2010 Dec 27.


New prognostic and predictive factors in breast cancer.

Schmidt M, Gehrmann M, Hengstler JG, Koelbl H.

Minerva Ginecol. 2010 Dec;62(6):599-611. Review.


Improved prognostic classification of breast cancer defined by antagonistic activation patterns of immune response pathway modules.

Teschendorff AE, Gomez S, Arenas A, El-Ashry D, Schmidt M, Gehrmann M, Caldas C.

BMC Cancer. 2010 Nov 4;10:604. doi: 10.1186/1471-2407-10-604.


Automated extraction of DNA and RNA from a single formalin-fixed paraffin-embedded tissue section for analysis of both single-nucleotide polymorphisms and mRNA expression.

Hennig G, Gehrmann M, Stropp U, Brauch H, Fritz P, Eichelbaum M, Schwab M, Schroth W.

Clin Chem. 2010 Dec;56(12):1845-53. doi: 10.1373/clinchem.2010.151233. Epub 2010 Oct 14.


Integration of pathway knowledge into a reweighted recursive feature elimination approach for risk stratification of cancer patients.

Johannes M, Brase JC, Fröhlich H, Gade S, Gehrmann M, Fälth M, Sültmann H, Beissbarth T.

Bioinformatics. 2010 Sep 1;26(17):2136-44. doi: 10.1093/bioinformatics/btq345. Epub 2010 Jun 30.


Role of thioredoxin reductase 1 and thioredoxin interacting protein in prognosis of breast cancer.

Cadenas C, Franckenstein D, Schmidt M, Gehrmann M, Hermes M, Geppert B, Schormann W, Maccoux LJ, Schug M, Schumann A, Wilhelm C, Freis E, Ickstadt K, Rahnenführer J, Baumbach JI, Sickmann A, Hengstler JG.

Breast Cancer Res. 2010;12(3):R44. doi: 10.1186/bcr2599. Epub 2010 Jun 28.


Radiation induced stress proteins.

Gehrmann M, Schilling D, Molls M, Multhoff G.

Int J Clin Pharmacol Ther. 2010 Jul;48(7):492-3. No abstract available.


Comparison of scores for bimodality of gene expression distributions and genome-wide evaluation of the prognostic relevance of high-scoring genes.

Hellwig B, Hengstler JG, Schmidt M, Gehrmann MC, Schormann W, Rahnenführer J.

BMC Bioinformatics. 2010 May 25;11:276. doi: 10.1186/1471-2105-11-276.


In vivo imaging of CT26 mouse tumours by using cmHsp70.1 monoclonal antibody.

Stangl S, Gehrmann M, Dressel R, Alves F, Dullin C, Themelis G, Ntziachristos V, Staeblein E, Walch A, Winkelmann I, Multhoff G.

J Cell Mol Med. 2011 Apr;15(4):874-87. doi: 10.1111/j.1582-4934.2010.01067.x.


ERBB2 and TOP2A in breast cancer: a comprehensive analysis of gene amplification, RNA levels, and protein expression and their influence on prognosis and prediction.

Brase JC, Schmidt M, Fischbach T, Sültmann H, Bojar H, Koelbl H, Hellwig B, Rahnenführer J, Hengstler JG, Gehrmann MC.

Clin Cancer Res. 2010 Apr 15;16(8):2391-401. doi: 10.1158/1078-0432.CCR-09-2471. Epub 2010 Apr 6.


Ep-CAM RNA expression predicts metastasis-free survival in three cohorts of untreated node-negative breast cancer.

Schmidt M, Petry IB, Böhm D, Lebrecht A, von Törne C, Gebhard S, Gerhold-Ay A, Cotarelo C, Battista M, Schormann W, Freis E, Selinski S, Ickstadt K, Rahnenführer J, Sebastian M, Schuler M, Koelbl H, Gehrmann M, Hengstler JG.

Breast Cancer Res Treat. 2011 Feb;125(3):637-46. doi: 10.1007/s10549-010-0856-5. Epub 2010 Mar 30.


ERBB2 induces an antiapoptotic expression pattern of Bcl-2 family members in node-negative breast cancer.

Petry IB, Fieber E, Schmidt M, Gehrmann M, Gebhard S, Hermes M, Schormann W, Selinski S, Freis E, Schwender H, Brulport M, Ickstadt K, Rahnenführer J, Maccoux L, West J, Kölbl H, Schuler M, Hengstler JG.

Clin Cancer Res. 2010 Jan 15;16(2):451-60. doi: 10.1158/1078-0432.CCR-09-1617. Epub 2010 Jan 12.


CDK10 is not a target for aberrant DNA methylation in breast cancer.

Heller G, Ziegler B, Brandstetter A, Novak S, Rudas M, Hennig G, Gehrmann M, Acht T, Zöchbauer-Müller S, Filipits M.

Anticancer Res. 2009 Oct;29(10):3939-44.


Exercise-induced extracellular 72 kDa heat shock protein (Hsp72) stimulates neutrophil phagocytic and fungicidal capacities via TLR-2.

Giraldo E, Martin-Cordero L, Garcia JJ, Gehrmann M, Multhoff G, Ortega E.

Eur J Appl Physiol. 2010 Jan;108(2):217-25. doi: 10.1007/s00421-009-1201-8. Epub 2009 Sep 22. Erratum in: Eur J Appl Physiol. 2011 Nov;111(11):2883. Gerhmann, Mathias [corrected to Gehrmann, Mathias].


A high-sensitivity, medium-density, and target amplification-free planar waveguide microarray system for gene expression analysis of formalin-fixed and paraffin-embedded tissue.

Schwers S, Reifenberger E, Gehrmann M, Izmailov A, Bohmann K.

Clin Chem. 2009 Nov;55(11):1995-2003. doi: 10.1373/clinchem.2009.128215. Epub 2009 Sep 10.


Anti-tumor activity of patient-derived NK cells after cell-based immunotherapy--a case report.

Milani V, Stangl S, Issels R, Gehrmann M, Wagner B, Hube K, Mayr D, Hiddemann W, Molls M, Multhoff G.

J Transl Med. 2009 Jun 23;7:50. doi: 10.1186/1479-5876-7-50.


Coordinates in the universe of node-negative breast cancer revisited.

Schmidt M, Hengstler JG, von Törne C, Koelbl H, Gehrmann MC.

Cancer Res. 2009 Apr 1;69(7):2695-8. doi: 10.1158/0008-5472.CAN-08-4013. Epub 2009 Mar 24. Review.


Binding of heat shock protein 70 to extracellular phosphatidylserine promotes killing of normoxic and hypoxic tumor cells.

Schilling D, Gehrmann M, Steinem C, De Maio A, Pockley AG, Abend M, Molls M, Multhoff G.

FASEB J. 2009 Aug;23(8):2467-77. doi: 10.1096/fj.08-125229. Epub 2009 Mar 16.


[Predictive and prognostic markers of breast cancer. Molecular biological analysis of fixed tumor tissue].

Petry C, Gehrmann M, von Törne C, Weber K, Stropp U, Hennig G.

Pathologe. 2008 Nov;29 Suppl 2:181-3. doi: 10.1007/s00292-008-1081-4. German.


Long-term outcome prediction by clinicopathological risk classification algorithms in node-negative breast cancer--comparison between Adjuvant!, St Gallen, and a novel risk algorithm used in the prospective randomized Node-Negative-Breast Cancer-3 (NNBC-3) trial.

Schmidt M, Victor A, Bratzel D, Boehm D, Cotarelo C, Lebrecht A, Siggelkow W, Hengstler JG, Elsässer A, Gehrmann M, Lehr HA, Koelbl H, von Minckwitz G, Harbeck N, Thomssen C.

Ann Oncol. 2009 Feb;20(2):258-64. doi: 10.1093/annonc/mdn590. Epub 2008 Sep 29.


Prognostic effect of epithelial cell adhesion molecule overexpression in untreated node-negative breast cancer.

Schmidt M, Hasenclever D, Schaeffer M, Boehm D, Cotarelo C, Steiner E, Lebrecht A, Siggelkow W, Weikel W, Schiffer-Petry I, Gebhard S, Pilch H, Gehrmann M, Lehr HA, Koelbl H, Hengstler JG, Schuler M.

Clin Cancer Res. 2008 Sep 15;14(18):5849-55. doi: 10.1158/1078-0432.CCR-08-0669.

Supplemental Content

Loading ...
Support Center